726 related articles for article (PubMed ID: 34691042)
41. Survey of Epstein Barr virus (EBV) immunogenic proteins and their epitopes: implications for vaccine preparation.
Rajcani J; Szenthe K; Banati F; Szathmary S
Recent Pat Antiinfect Drug Discov; 2014; 9(1):62-76. PubMed ID: 25164057
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
Herrman M; Mühe J; Quink C; Wang F
J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
[TBL] [Abstract][Full Text] [Related]
43. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy.
Dudaniec K; Westendorf K; Nössner E; Uckert W
Hum Gene Ther; 2021 Sep; 32(17-18):919-935. PubMed ID: 33798008
[TBL] [Abstract][Full Text] [Related]
44. The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment.
Chen J; Jardetzky TS; Longnecker R
mBio; 2016 Nov; 7(6):. PubMed ID: 27935841
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.
Lockey TD; Zhan X; Surman S; Sample CE; Hurwitz JL
Front Biosci; 2008 May; 13():5916-27. PubMed ID: 18508632
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
47. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
Dasari V; Sinha D; Neller MA; Smith C; Khanna R
Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
[TBL] [Abstract][Full Text] [Related]
49. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination.
Stewart JP; Micali N; Usherwood EJ; Bonina L; Nash AA
Vaccine; 1999 Jan; 17(2):152-7. PubMed ID: 9987149
[TBL] [Abstract][Full Text] [Related]
50. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
52. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
53. Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.
Dasari V; McNeil LK; Beckett K; Solomon M; Ambalathingal G; Thuy TL; Panikkar A; Smith C; Steinbuck MP; Jakubowski A; Seenappa LM; Palmer E; Zhang J; Haqq CM; DeMuth PC; Khanna R
Nat Commun; 2023 Aug; 14(1):4371. PubMed ID: 37553346
[TBL] [Abstract][Full Text] [Related]
54. The need and challenges for development of an Epstein-Barr virus vaccine.
Cohen JI; Mocarski ES; Raab-Traub N; Corey L; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2(0 2):B194-6. PubMed ID: 23598481
[TBL] [Abstract][Full Text] [Related]
55. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.
Sun C; Chen XC; Kang YF; Zeng MS
Front Immunol; 2021; 12():677027. PubMed ID: 34168649
[TBL] [Abstract][Full Text] [Related]
56. Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary MicroRNA.
Correia S; Palser A; Elgueta Karstegl C; Middeldorp JM; Ramayanti O; Cohen JI; Hildesheim A; Fellner MD; Wiels J; White RE; Kellam P; Farrell PJ
J Virol; 2017 Aug; 91(15):. PubMed ID: 28515295
[TBL] [Abstract][Full Text] [Related]
57. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
58. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
[TBL] [Abstract][Full Text] [Related]
59. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
Jackman WT; Mann KA; Hoffmann HJ; Spaete RR
Vaccine; 1999 Feb; 17(7-8):660-8. PubMed ID: 10067671
[TBL] [Abstract][Full Text] [Related]
60. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
Chen WH; Kim J; Bu W; Board NL; Tsybovsky Y; Wang Y; Hostal A; Andrews SF; Gillespie RA; Choe M; Stephens T; Yang ES; Pegu A; Peterson CE; Fisher BE; Mascola JR; Pittaluga S; McDermott AB; Kanekiyo M; Joyce MG; Cohen JI
Immunity; 2022 Nov; 55(11):2135-2148.e6. PubMed ID: 36306784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
